Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewIEM 1925 dihydrobromide is a voltage- and use-dependent open-channel antagonist of AMPA receptors. Selective between subtypes; blocks GluA2 subunit-lacking receptors more potently than GluA2-containing receptors (KD for GluA2-containing AMPAR is 210 times higher at -80 mV). More potent than IEM 1460 (Cat. No. 1636) and IEM 1754 due to a slower unblocking rate. Alleviates inflammatory pain in a rat model of peripheral inflammation.
M. Wt | 422.24 |
Formula | C17H28N2.2HBr |
Storage | Desiccate at RT |
Purity | ≥95% (HPLC) |
CAS Number | 258282-23-4 |
PubChem ID | 44561101 |
InChI Key | ZCYUSVRXEKAQSL-UHFFFAOYSA-N |
Smiles | NCCCCCNC1(C2=CC=CC=C2)CCCCC1.Br.Br |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solvent | Max Conc. mg/mL | Max Conc. mM | |
---|---|---|---|
Solubility | |||
water | 42.22 | 100 | |
DMSO | 21.11 | 50 |
The following data is based on the product molecular weight 422.24. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 2.37 mL | 11.84 mL | 23.68 mL |
5 mM | 0.47 mL | 2.37 mL | 4.74 mL |
10 mM | 0.24 mL | 1.18 mL | 2.37 mL |
50 mM | 0.05 mL | 0.24 mL | 0.47 mL |
References are publications that support the biological activity of the product.
Tikhonov et al (2000) Voltage-dependent block of native AMPA receptor channels by dicationic compounds. Br.J.Pharmacol. 129 265 PMID: 10694232
Kopach et al (2016) Inhibition of spinal Ca2+-permeable AMPA receptors with dicationic compounds alleviates persistent inflammatory pain without adverse effects. Front.Cell Neurosci. 10 PMID: 26973464
If you know of a relevant reference for IEM 1925 dihydrobromide, please let us know.
Keywords: IEM 1925 dihydrobromide, IEM 1925 dihydrobromide supplier, IEM1925, 2HBr, AMPAR, antagonist, blocks, AMPA, receptor, voltage-dependent, channel, blocker, Receptors, 4198, Tocris Bioscience
Citations are publications that use Tocris products. Selected citations for IEM 1925 dihydrobromide include:
Ondrej et al (2021) Gating and modulation of a hetero-octameric AMPA glutamate receptor. Nature 594 454-458 PMID: 34079129
Terunaga et al (2023) Modulatory mechanisms of TARP γ8-selective AMPA receptor therapeutics. Nat Commun 14 1659 PMID: 36966141
Do you know of a great paper that uses IEM 1925 dihydrobromide from Tocris? Please let us know.
There are currently no reviews for this product. Be the first to review IEM 1925 dihydrobromide and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.